A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients. (December 2021) - Le Tourneau, C.; Calugaru, V.; Moreno, V.; Calvo, E.; Liem, X.; Salas, S.; Doger, B.; Jouffroy, T.; Mirabel, X.; Rodriguez, J.; Chilles, A.; Bernois, K.; et al.